TABLE 1.
SGLT2i Cardiovascular Outcome Trials
| EMPA-REG Empagliflozin (n = 7,020) | CANVAS Program Canagliflozin (n = 10,142) | DECLARE Dapagliflozin (n = 17,160) | CREDENCE Canagliflozin (n = 4,401) | DAPA-HF Dapagliflozin (n = 4744) | |
|---|---|---|---|---|---|
| Median follow-up, yrs | 3.1 | 2.4 | 4.2 | 2.6 | 1.5 |
| Mean age, yrs | 63 | 63 | 64 | 63 | 66 |
| Female, % | 29 | 36 | 37 | 34 | 23 |
| BMI, kg/m2 | 30.6 | 32.0 | 32.1 | 31.3 | 28.2 |
| HbA1c, % | 8.1 | 8.3 | 8.3 | 8.3 | NR |
| Baseline metformin, %* | 73 | 77 | 82 | 66 | 73 |
| Baseline eGFR† | 74 | 77 | 85 | 56 | 65 |
| eGFR† <60 ml/min, % | 26 | 20 | 7 | 59 | 40 |
| Prior CVD, % | 99 | 66 | 41 | 50 | |
| Prior HF, % | 10 | 14 | 10 | 15 | |
| 3P-MACE | 0.86 (0.74–0.99) | 0.86 (0.67–0.91) | 0.93 (0.84–1.03) | 0.80 (0.67–0.95) | 0.74 (0.65–0.85) |
| CV death | 0.62 (0.49–0.77) | 0.87 (0.72–1.06) | 0.98 (0.82–1.17) | 0.78 (0.61–1.00) | 0.75 (0.65–0.85) |
| Nonfatal MI | 0.87 (0.70–1.09) | 0.89 (0.73–1.09) | 0.89 (0.77–1.01) | NR | 0.82 (0.69–0.98) |
| Nonfatal stroke | 1.18 (0.89–1.56) | 0.87 (0.69–1.09) | 1.01 (0.84–1.21) | NR | 0.83 (0.71–0.97) |
| CV death or HHF | 0.66 (0.55–0.79) | 0.78 (0.67–0.91) | 0.83 (0.73–0.95) | 0.69 (0.57–0.83) | |
| All-cause mortality | 0.68 (0.57–0.82) | 0.87 (0.74–1.01) | 0.93 (0.82–1.04) | 0.83 (0.68–1.02) | |
| HHF | 0.65 (0.50–0.85) | 0.67 (0.52–0.87) | 0.73 (0.61–0.88) | 0.61 (0.47–0.80) | 0.70 (0.59–0.83) |
| Renal events‡ | 0.61 (0.53–0.70) | 0.60 (0.47–0.77) | 0.53 (0.43–0.66) | 0.70 (0.59–0.82) | 0.83 (0.44–1.16) |
Values are hazard ratio (confidence interval) unless otherwise indicated.
*
Average of entire study group (treatment and control).
†
eGFR units ml/min/1.73 m2.
‡
Definition varied across trials.
CANVAS = ■■■; CREDENCE = ■■■; DAPA-HF = ■■■; DECLARE = ■■■; EMPA-REG = ■■■; SGLT21 = sodium glucose cotransporter 2 inhibitor; other abbreviations as in Table 1.